The U.S. Food and Drug Administration approved Sotyktu (deucravacitinib) on March 6, 2026, for the treatment of adults with active psoriatic arthritis, making it the first and only tyrosine kinase 2 (TYK2) inhibitor cleared for this condition. Manufactured by Bristol Myers Squibb, the once-daily oral tablet represents a meaningful shift in how psoriatic arthritis can be managed — particularly for patients who prefer a pill over injections or infusions.
In clinical trials involving nearly 1,300 participants, 54% of patients taking deucravacitinib achieved at least a 20% improvement in signs and symptoms at 16 weeks, compared to roughly 34-39% on placebo. For people living with psoriatic arthritis, a disease that attacks both the skin and joints with chronic inflammation, treatment options have historically leaned on biologics that require needles or older drugs with broad immunosuppressive effects. Sotyktu carves out a different path by selectively targeting TYK2, a single enzyme in the inflammatory cascade, rather than suppressing the immune system more broadly. This article examines how the drug works, what the trial data actually showed, safety concerns patients should discuss with their doctors, how it compares to existing treatments, and what the approval might signal for the future of psoriatic arthritis care.
Table of Contents
- What Does the FDA Approval of This New Small Molecule Drug for Psoriatic Arthritis Mean for Patients?
- How Deucravacitinib Targets Inflammation Differently Than Traditional JAK Inhibitors
- What the POETYK Clinical Trials Revealed About Efficacy
- How Sotyktu Compares to Existing Psoriatic Arthritis Treatments
- Safety Concerns and What Patients Should Discuss With Their Doctors
- The Connection Between Psoriatic Arthritis, Chronic Inflammation, and Brain Health
- What Is Next in the Psoriatic Arthritis Treatment Pipeline
- Conclusion
- Frequently Asked Questions
What Does the FDA Approval of This New Small Molecule Drug for Psoriatic Arthritis Mean for Patients?
The approval of deucravacitinib for psoriatic arthritis marks the drug’s second FDA-approved indication. Bristol Myers Squibb first secured approval for Sotyktu in September 2022 for moderate-to-severe plaque psoriasis, a related but distinct skin condition. The supplemental New Drug Application for psoriatic arthritis was accepted for review across four regions globally in 2025, with the FDA setting a target action date of March 6, 2026 — a deadline the agency met. For rheumatologists and dermatologists who already had experience prescribing the drug for psoriasis, the expanded label means they can now offer it to patients whose disease has progressed to joint involvement without switching to an entirely different medication.
What makes this notable is the “small molecule” designation. Unlike biologics such as adalimumab or secukinumab, which are large protein-based drugs requiring injection or infusion, deucravacitinib is a small molecule taken as a single 6 mg tablet once daily. that distinction matters in practice. A patient who dreads self-injection or who has trouble getting to an infusion center now has an oral option that specifically targets the inflammatory pathway driving their disease. It is worth noting, however, that “oral” does not automatically mean “easier” — every drug carries its own monitoring requirements and potential side effects, and some patients do better on biologics than on oral agents.
How Deucravacitinib Targets Inflammation Differently Than Traditional JAK Inhibitors
Deucravacitinib belongs to a class of drugs that inhibit Janus kinase pathways, but it differs from traditional JAK inhibitors like tofacitinib or upadacitinib in a critical way. Conventional JAK inhibitors block multiple JAK enzymes (JAK1, JAK2, JAK3), which can dampen a wide range of immune signals. That broad suppression is effective but has raised safety concerns — the FDA has placed boxed warnings on several JAK inhibitors regarding risks of cardiovascular events, blood clots, and malignancies. Deucravacitinib sidesteps this problem by selectively inhibiting only TYK2, and it does so through an allosteric mechanism, meaning it binds to a regulatory region of the enzyme rather than its active site. TYK2 plays a specific role in signaling pathways for interleukin-23, interleukin-12, and type I interferons — cytokines that are directly implicated in the inflammation seen in psoriatic arthritis.
By narrowing its target to TYK2 alone, deucravacitinib aims to reduce the inflammatory drivers of the disease while leaving other parts of the immune system less disturbed. However, selective does not mean risk-free. The drug’s label still carries warnings for hypersensitivity reactions, infections, tuberculosis, malignancy including lymphomas, rhabdomyolysis and elevated CPK levels, laboratory abnormalities, and immunization considerations. Patients with a history of serious infections or those on immunosuppressive therapies should have a thorough conversation with their physician before starting treatment. It is also important to manage expectations around the word “selective.” While the mechanism is more targeted than older JAK inhibitors, long-term safety data in the psoriatic arthritis population is still accumulating. The trials that supported approval ran for limited durations, and rare adverse events sometimes only emerge after years of widespread use.
What the POETYK Clinical Trials Revealed About Efficacy
The FDA’s approval rested on data from two Phase 3 clinical trials: POETYK PsA-1 and POETYK PsA-2. The first enrolled 670 patients who had never been treated with a biologic, while the second enrolled 624 patients, including those who had previously tried and either failed or stopped a biologic therapy. Both trials used the same primary endpoint: the proportion of patients achieving ACR20, a standard rheumatology measure that indicates at least a 20% improvement in joint tenderness, swelling, and other disease markers, at 16 weeks. In POETYK PsA-1, 54% of patients on deucravacitinib hit the ACR20 mark compared to 34% on placebo. POETYK PsA-2 showed a similar result — 54% versus 39%.
Both trials met their primary endpoints with statistical significance, and both also demonstrated incremental improvements at the higher ACR50 and ACR70 thresholds, meaning some patients saw 50% or even 70% improvement in their symptoms. To put that in real terms, a patient who had been struggling with swollen, painful knuckles and stiff mornings might, after 16 weeks on the drug, be able to button a shirt or open a jar with noticeably less difficulty. That said, a 54% ACR20 response rate means roughly half of patients did not achieve even a 20% improvement. Clinical trial populations are carefully selected, and real-world results can differ. Patients who have failed multiple prior therapies, who have significant comorbidities, or whose disease has caused irreversible joint damage may see less benefit. The trials provide a solid foundation, but they do not promise a cure or even remission for most patients.
How Sotyktu Compares to Existing Psoriatic Arthritis Treatments
The treatment landscape for psoriatic arthritis has grown considerably over the past two decades, and patients now have options that range from conventional disease-modifying drugs like methotrexate to targeted biologics and now oral small molecules. Methotrexate remains a first-line therapy for many patients, but it requires regular blood monitoring, can cause liver toxicity, and does not work well for everyone. Biologics targeting TNF-alpha, IL-17, or IL-23 have demonstrated strong efficacy but require injection or infusion, which some patients find burdensome or anxiety-inducing. Deucravacitinib occupies a space between these categories. Compared to tofacitinib, another oral option, it offers a more selective mechanism that may carry fewer systemic risks — though head-to-head trial data comparing the two drugs in psoriatic arthritis is not yet available.
Compared to injectable biologics like secukinumab or guselkumab, the convenience of a once-daily pill is appealing, but some biologics have demonstrated higher ACR response rates in their own trials. Direct comparisons across trials are unreliable because of differences in patient populations, placebo response rates, and study design, so patients and physicians will need to weigh individual factors: prior treatment history, comfort with injections, insurance coverage, and specific disease manifestations. One practical tradeoff worth mentioning is cost and access. New branded medications often carry high list prices, and insurance formularies may not cover a newly approved indication right away. A patient excited about switching to an oral option may find that their plan requires them to try and fail one or more other therapies before covering Sotyktu, a process known as step therapy that can delay treatment for months.
Safety Concerns and What Patients Should Discuss With Their Doctors
No drug approval comes without a careful accounting of risk. The FDA-approved label for deucravacitinib in psoriatic arthritis includes warnings for several categories that patients should understand before starting therapy. Infections are a primary concern — because the drug modulates immune signaling, it can reduce the body’s ability to fight off bacterial, viral, and fungal infections. Patients should be tested for tuberculosis before starting treatment, and those with active infections should not begin the drug until the infection is resolved. The label also flags rhabdomyolysis and elevated creatine phosphokinase (CPK) levels, a less commonly discussed risk that is particularly relevant for physically active patients or those on statin medications.
Symptoms of rhabdomyolysis include severe muscle pain, weakness, and dark urine, and patients should be counseled to report these immediately. Malignancy risk, including lymphomas, is mentioned as well, consistent with other immunomodulatory therapies, though the absolute risk in clinical trials was low. Immunization timing is another practical consideration. Live vaccines should generally be avoided while on deucravacitinib, which means patients should ensure their vaccinations — including shingles, which is more common in immunosuppressed individuals — are up to date before beginning treatment. For older adults or those with multiple comorbidities, this requires coordination with their primary care provider, not just their rheumatologist.
The Connection Between Psoriatic Arthritis, Chronic Inflammation, and Brain Health
For readers of a brain health and dementia care site, the approval of a new anti-inflammatory drug for psoriatic arthritis may seem tangential, but there is a growing body of research connecting chronic systemic inflammation to cognitive decline and neurodegenerative disease. Psoriatic arthritis, like rheumatoid arthritis and other autoimmune conditions, generates persistent inflammatory signals — elevated IL-23, IL-12, and interferon levels — that circulate throughout the body, including the brain. Several population-level studies have found that people with chronic inflammatory diseases face a modestly increased risk of dementia compared to the general population, though the mechanisms are still being worked out. This does not mean that treating psoriatic arthritis with deucravacitinib will prevent dementia.
That claim would be premature and unsupported by current evidence. But it does underscore why managing chronic inflammatory conditions matters beyond joint pain and skin lesions. Uncontrolled systemic inflammation can compound other risk factors for cognitive decline, particularly in older adults who may already be managing hypertension, diabetes, or cardiovascular disease. For caregivers and families navigating both autoimmune disease and concerns about cognitive health, having effective treatment options for the inflammatory condition is one piece of a larger puzzle.
What Is Next in the Psoriatic Arthritis Treatment Pipeline
Deucravacitinib is not the only new option on the horizon. Tildrakizumab, marketed as Ilumya by Sun Pharma, is a biologic targeting IL-23 that already has FDA approval for plaque psoriasis. A supplemental Biologics License Application for psoriatic arthritis has been accepted by the FDA, with a regulatory action date expected by October 29, 2026. If approved, it would add another IL-23-targeted option to the biologic category.
Meanwhile, Takeda is developing zasocitinib, another TYK2 inhibitor currently in Phase 3 trials for plaque psoriasis, with a New Drug Application submission planned for fiscal year 2026 and further evaluation underway for psoriatic arthritis. The trend is clear: the field is moving toward more targeted therapies that aim to control disease with fewer off-target effects. For patients and their physicians, more options generally mean better chances of finding a treatment that works well with an acceptable side effect profile. But more options also mean more complex decision-making, and patients should expect that treatment plans for psoriatic arthritis will increasingly be tailored rather than one-size-fits-all.
Conclusion
The FDA’s approval of Sotyktu for active psoriatic arthritis on March 6, 2026, adds a genuinely new mechanism to the treatment toolkit — the first oral TYK2 inhibitor for this condition. With clinical trial data showing that 54% of patients achieved meaningful symptom improvement at 16 weeks and a once-daily dosing schedule, it addresses real gaps in convenience and targeted therapy.
At the same time, the drug is not without risks, and its long-term safety profile in psoriatic arthritis will only become clear with broader use and post-marketing surveillance. For patients, the practical next step is a conversation with their rheumatologist about whether deucravacitinib fits their specific situation — considering their treatment history, disease severity, other medications, and personal preferences around oral versus injectable therapies. For those managing chronic inflammation alongside concerns about cognitive health or dementia risk, keeping autoimmune disease well-controlled remains an important part of overall health maintenance, even if the direct links between specific treatments and brain outcomes are still being studied.
Frequently Asked Questions
Is Sotyktu (deucravacitinib) a JAK inhibitor?
Not in the traditional sense. It selectively inhibits TYK2, which is part of the JAK family, but it does not broadly suppress JAK1, JAK2, or JAK3 the way older JAK inhibitors do. This selective mechanism is designed to reduce certain inflammatory signals while leaving others intact.
Can I take Sotyktu as a pill instead of getting injections for psoriatic arthritis?
Yes. Deucravacitinib is taken as a single 6 mg oral tablet once daily, making it an alternative for patients who prefer not to use injectable biologics. However, whether it is the right choice depends on your specific disease profile and treatment history.
What were the main side effects seen in the clinical trials?
The drug label includes warnings for infections, tuberculosis, hypersensitivity reactions, malignancy including lymphomas, rhabdomyolysis and elevated CPK levels, and laboratory abnormalities. Live vaccines should also be avoided during treatment.
Does Sotyktu work for people who have already tried biologic therapies?
The POETYK PsA-2 trial included patients who had previously used biologics, and the drug still showed a statistically significant improvement over placebo (54% ACR20 versus 39%). However, patients with extensive prior treatment failures may respond differently than those in clinical trials.
Is there a connection between psoriatic arthritis treatment and dementia risk?
Chronic systemic inflammation, including the kind generated by psoriatic arthritis, has been associated with a modestly increased risk of cognitive decline in population studies. While no psoriatic arthritis drug has been proven to reduce dementia risk, managing inflammation is generally considered beneficial for overall brain health.
